Application | Comment | Organism |
---|---|---|
drug development | the PI3K/Akt signaling pathway is a therapeutic target in treatment of medulloblastoma disease, a primitive neuroectodermal tumor, and the most common malignant pediatric brain tumor | Homo sapiens |
Inhibitors | Comment | Organism | Structure |
---|---|---|---|
additional information | small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth. The inhibitors affect beta-catenin signaling by inhibition of GSK-3beta activity, resulting in cytoplasmic retention of beta-catenin and reduced expression of its target genes cyclin D1 and c-Myc | Homo sapiens |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Homo sapiens | - |
clinical samples from Schwedish patients | - |
Source Tissue | Comment | Organism | Textmining |
---|---|---|---|
brain | - |
Homo sapiens | - |
medulloblastoma cell | - |
Homo sapiens | - |
Synonyms | Comment | Organism |
---|---|---|
PI3K | - |
Homo sapiens |
General Information | Comment | Organism |
---|---|---|
malfunction | the phosphatidylinositol 3-kinase/Akt signaling pathway is crucial to sustain the pathophysiology of medulloblastoma, a primitive neuroectodermal tumor and the most common malignant pediatric brain tumor. Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth. The inhibitors affect beta-catenin signaling by inhibition of GSK-3beta activity, resulting in cytoplasmic retention of beta-catenin and reduced expression of its target genes cyclin D1 and c-Myc | Homo sapiens |
metabolism | the enzyme is part of the phosphatidylinositol 3-kinase/Akt signaling pathway | Homo sapiens |